First Commercial Procedures Performed Using Corindus Vascular Robotics’ CorPath GRX System

Corindus Vascular Robotics Inc., a developer of precision vascular robotics, announced that the first commercial procedures have been performed using its CorPath GRX System following the company’s recent 510(k) clearance from the U.S. Food and Drug Administration (FDA). In early February, NewYork-Presbyterian, UC San Diego Health, and University of Virginia Health System used the CorPath GRX System to perform robotic-assisted PCI procedures. Corindus began limited installations of the CorPath GRX System in January 2017 with plans for a full commercial launch later this month.
 
Hospital programs provided positive feedback on their initial experience with the CorPath GRX System.

“We are proud to be among the group of premier hospitals that performed the first cases in the world using the new CorPath GRX System. The enhancements provided by CorPath GRX represent a dramatic improvement in the capabilities in robotic PCI and have the potential to provide significant improvements in patient care,” said Manish Parikh, M.D., associate director of the Cardiac Catheterization laboratory at NewYork-Presbyterian Hospital. 
 
“I am impressed with the additional capabilities of the new GRX System. The redesigned bedside unit, intuitive control console, and especially guide catheter control further facilitate complex PCI procedures. It also enables me to train other interventionalists and fellows in state-of-the-art robotics,” added Ehtisham Mahmud, M.D., division chief of UC San Diego Health, Cardiovascular Medicine and medical director of the Sulpizio Cardiovascular Center.

“The CorPath GRX System provides me with complete robotic control during complex PCI procedures. Using CorPath GRX and its radiation-shielded cockpit has enabled me to expand the number of procedures I can perform,” said Michael Ragosta, M.D., an interventional cardiologist.
 
CorPath GRX offers enhancements to the CorPath platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. The Active Guide Management feature allows interventional cardiologists to control the guide catheter, which was not possible with the first generation technology.

Physicians now have independent and simultaneous robotic control of guide catheters, guidewires, and balloon/stent catheters, with one-millimeter advancement, from the cockpit console. This precise positioning that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases. CorPath GRX also features a completely redesigned bedside unit featuring an extended reach arm and touchscreen display to streamline workflow.
 
“Completion of these initial CorPath GRX procedures marks an important step forward in vascular robotics,” said Mark Toland, president and CEO of Corindus Vascular Robotics.
 
Corindus Vascular Robotics Inc. develops robotic-assisted vascular interventional technology. The company’s CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. The company is based in Waltham, Mass.